Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Carmustine (BCNU)

3

XV.h Path: NSIP-fibrotic pattern

1
Last update : 18/02/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Bendamustine
1
Fotemustine
1
Lomustine (CCNU)
3
Nitrosoureas (suffixes '-NU', '-mustine')
4

Publications

Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.
Mayo Clinic proceedings 2003 May;78;630-4 2003 May
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
The Journal of pathology 1991 May;164;31-6 1991 May
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
The New England journal of medicine 1990 Aug 09;323;378-82 1990 Aug 09
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Cancer 1984 Aug 15;54;751-5 1984 Aug 15
Pulmonary fibrosis following low-dose 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Cancer 1980 Mar 15;45;1311-4 1980 Mar 15
Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy.
Cancer 1979 May;43;1607-12 1979 May
Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Cancer 1978 Jul;42;74-6 1978 Jul

Powered by

  • ^
  • Contact
  • Cookies
  • About